Bregal Milestone Announces Strategic Growth Investment in Ridango
Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in Ridango, a global provider of mission-critical public transportation software. The investment is made in partnership with founder Erki Lipre and the Ridango management team. Terms of the transaction were not disclosed.
Founded in 2009, Ridango is a global market leader in intelligent transportation software for public transport authorities, municipalities, cities, and private transport operators. Ridango has built one of the world’s leading integrated automated fare collection and operations control software platforms, serving more than 150 customers in over 25 countries across five continents. The Company’s modern software provides end-to-end transit management services, from account-based ticketing to contactless bank card acceptance, real-time passenger information, and automatic vehicle location operations management to deliver better transit services, more accurate real-time visibility, and improved passenger satisfaction.
With operational and financial support from Bregal Milestone, Ridango aims to accelerate its organic and inorganic growth. Following accelerated customer activity in Sweden, including customer wins from Västtrafik, Sörmlandstrafiken, and Västmanlandstrafiken, the Company will operate from its new European headquarters in Sweden; its R&D hubs in Estonia and Slovenia; and its regional sales and marketing hubs following major customer wins in the Middle East (UAE, Qatar, and Saudi Arabia) and APAC (Singapore and Hong Kong).
“Our partnership with Bregal Milestone marks a significant next step in our growth strategy. We extend our sincerest thanks to our prior investors, BaltCap Private Equity, and look forward to the proactive support and expertise from Bregal Milestone and their in-house value creation team, Milestone Performance Partners, to help accelerate our investment in next-generation technology and accelerate our GTM activity in new markets,” said Erki Lipre, Founder and CEO of Ridango. "Public transportation is at the heart of sustainable urban development, and the team at Ridango is tirelessly committed to delivering the most advanced solutions to help modernize transit networks for the future."
“Ridango’s strong commitment to innovation has positioned it as a software operating system of choice for transit operators looking to modernize fare collection and optimize passenger experience,” added Cyrus Shey, Managing Partner at Bregal Milestone. “We see strong secular tailwinds as private transport operators and public rail and mass transport operators accelerate investments in digitalization, underpinned by the accelerated shift from card-based ticketing to account-based ticketing systems, and we are thrilled to partner with Erki and his leadership team to support Ridango in capitalizing on these megatrends.”
Sebastian Charpentier, Principal at Bregal Milestone, adds, “We are honored to enter this strategic partnership with Ridango, a company that continues to drive innovation and deliver customer service with what we see as the most advanced end-to-end transit software offerings featuring AI-driven predictive analytics and cloud-based fare collection. We believe that Ridango is uniquely positioned to lead the digital transformation for public transportation authorities and operators alike, creating sustainable long-term value for the communities in which they operate.”
White & Case served as legal counsel and Deloitte as financial advisor for Bregal Milestone. Sorainen served as legal counsel for Ridango.
The transaction will be closed after necessary regulatory approvals have been obtained.
About Bregal Milestone
Bregal Milestone is a leading software and technology private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading technology companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with assets under management of over €19 billion. Bregal Milestone was recognised by GrowthCap as one of the Top Growth Equity Firms of 2024. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
About Ridango
Ridango is the software operating system of choice for public transportation providers globally, specializing in automated fare collection (“AFC”), real-time passenger information systems, automatic vehicle location tracking (“AVL”), and mobility-as-a-service (“MaaS”) technology. The company partners with transport authorities and operators to enhance the efficiency, accessibility, and sustainability of public transit for customers and operators alike.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319073578/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom